Synonyms: BI-397 | BI397 | Dalvance® | Xydalba®
dalbavancin is an approved drug (FDA (2014), EMA (2015))
Compound class:
Synthetic organic
Comment: Dalbavancin is a second-generation, semi-synthetic lipoglycopeptide antibacterial [1-2]. It has been modified to increase activity and allow once-weekly dosing. Dalbavancin inhibits cross-linking of bacterial cell wall peptidoglycans, and thereby disrupts bacterial cell wall synthesis. It has little activity against Gram-negative bacilli [3].
|
|
References |
1. Candiani G, Abbondi M, Borgonovi M, Romanò G, Parenti F. (1999)
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother, 44 (2): 179-92. [PMID:10473224] |
2. Jones RN, Biedenbach DJ, Johnson DM, Pfaller MA. (2001)
In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J Chemother, 13 (3): 244-54. [PMID:11450881] |
3. Roecker AM, Pope SD. (2008)
Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Expert Opin Pharmacother, 9 (10): 1745-54. [PMID:18570607] |